Analysis of the Potential Savings of Rivaroxaban Events Versus Vitamin K Antagonists Events

Estimate of Costs Associated With Atrial Fibrillation Treatment With Rivaroxaban Versus Vitamin K Antagonists

The main objective of this project is to evaluate savings in direct costs as regards the use of rivaroxaban versus vitamin K antagonists (VKAs) in routine clinical practice using data from three cohorts of patients receiving VKAs or rivaroxaban in Spain, including the time in therapeutic range (TTR) values of the same and the incidence of events in the first year following diagnosis.

Inclusion Criteria:

• Older than 18 years
• Diagnosis of non-valvular AF (ICD code 427.31)
• Pharmacological treatment with VKAs or rivaroxaban following diagnosis

Exclusion Criteria:

-